For research use only. Not for therapeutic Use.
Lapaquistat（Cat No.:I017939）is a synthetic small-molecule inhibitor of squalene synthase, a key enzyme in the cholesterol biosynthesis pathway. By blocking the conversion of farnesyl pyrophosphate to squalene, it reduces endogenous cholesterol production without affecting upstream isoprenoid metabolites. Developed as a potential lipid-lowering therapy, Lapaquistat aimed to provide an alternative to statins, with the promise of fewer muscle-related side effects. Although clinical trials showed significant cholesterol reduction, development was discontinued due to concerns over liver toxicity. Nonetheless, Lapaquistat remains important in research on cholesterol metabolism and cardiovascular disease.
| CAS Number | 189059-71-0 |
| Synonyms | 2-[1-[2-[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-5H-4,1-benzoxazepin-3-yl]acetyl]piperidin-4-yl]acetic acid |
| Molecular Formula | C31H39ClN2O8 |
| Purity | ≥95% |
| IUPAC Name | 2-[1-[2-[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(3-hydroxy-2,2-dimethylpropyl)-2-oxo-5H-4,1-benzoxazepin-3-yl]acetyl]piperidin-4-yl]acetic acid |
| InChI | InChI=1S/C31H39ClN2O8/c1-31(2,18-35)17-34-23-9-8-20(32)15-22(23)28(21-6-5-7-24(40-3)29(21)41-4)42-25(30(34)39)16-26(36)33-12-10-19(11-13-33)14-27(37)38/h5-9,15,19,25,28,35H,10-14,16-18H2,1-4H3,(H,37,38)/t25-,28-/m1/s1 |
| InChIKey | HDGUKVZPMPJBFK-LEAFIULHSA-N |
| SMILES | CC(C)(CN1C2=C(C=C(C=C2)Cl)[C@H](O[C@@H](C1=O)CC(=O)N3CCC(CC3)CC(=O)O)C4=C(C(=CC=C4)OC)OC)CO |
| Chemistry Calculators | Dilution Calculator In vivo Formulation Calculator Molarity Calculator Molecular Weight Calculator Reconstitution Calculator |
